CAJ | 학술논문

目的探讨尿激酶静脉溶栓治疗急性期椎基底动脉系统缺血性卒中的临床疗效.方法 13例急性期椎基底动脉系统缺血性卒中患者经静脉输注尿激酶50-150万U,并进行溶栓前、溶栓后即刻、6h、24h、7d、14d的美国围立卫生研究院卒中量表(NIHSS)评分.3个月时进行MRS评分以评定预后. 结果 13例患者在溶栓前NIHSS评分平均为(17.46-6.19)分,溶栓后评分呈下降趋势,溶栓后即刻为(11.77±6.47)分,溶栓后6 h为(10.31±5.65)分.24 h为(7.92±6.43)分,7 d为(6.58±5.41)分.14d为(6.50±5.56)分.溶栓后24h后的时间段NIHSS评分与溶栓前相比均明显减少,差异有统计学意义(P<0.05).13例中有3例死亡,2例预后不佳,8例预后良好.4例出现出血并发症,其中脑出血2例. 结论尿激酶静脉溶栓治疗可有效改善急性期椎基底动脉系统缺血性脑卒中的临床症状和预后.
목적 탐토뇨격매정맥용전치료급성기추기저동맥계통결혈성졸중적림상료효.방법 13례급성기추기저동맥계통결혈성졸중환자경정맥수주뇨격매50-150만U,병진행용전전、용전후즉각、6h、24h、7d、14d적미국위립위생연구원졸중량표(NIHSS)평분.3개월시진행MRS평분이평정예후. 결과 13례환자재용전전NIHSS평분평균위(17.46-6.19)분,용전후평분정하강추세,용전후즉각위(11.77±6.47)분,용전후6 h위(10.31±5.65)분.24 h위(7.92±6.43)분,7 d위(6.58±5.41)분.14d위(6.50±5.56)분.용전후24h후적시간단NIHSS평분여용전전상비균명현감소,차이유통계학의의(P<0.05).13례중유3례사망,2례예후불가,8례예후량호.4례출현출혈병발증,기중뇌출혈2례. 결론 뇨격매정맥용전치료가유효개선급성기추기저동맥계통결혈성뇌졸중적림상증상화예후.
Objective To evaluate the effect of intravenous thrombolysis with urokinasc for treatment of acute cerebral infarction due to vertebrobasilar artery ischemia.Methods Thirteen pafients with a clinical diagnosis of acute cerebral infarction arising from vertebrobasilar artery ischemia received thmmbolytic therapy with urokinase(5×105-1.5×106U) infused intravenously within 1 h.The NIH Stroke Scale(NIHSS)was used to evaluate the patients'neurological function before and at 0,6,24 hand at 7 and 14 days after the treatment.Modified Rankin Scale(MRS)was used for neurologiical assessment 3 months after the treatments. Results The mean NIHSS score of the patients was 17.46±6.19 before treatment and rapidly decreased to 7.92±6.43 24 h after the thrombolytic therapy.Three months after the therapy,8 patients had favorable clinical outcomes defined as capability of independent living(MRS score of 0-2);2 patients had a poor outcomes with assisted living,and 3 patients died.Bleeding occurred in 4 cases including 2 cerebral hemorrhage cases. Conclusion Favorable clinical outcome can be achieved with intravenous urokinase therapy in the majority of patients with acute cerebral infarction due to vertebrobasilar ischcrnia.